GENELUX Corp (GNLX)
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Genelux Corporation
NASDAQ:GNLXHealthcare · Biotechnology
-4.50%$1.91
AH Close$1.91+0.00%vs close
AH Close$1.91+0.00%vs close
Mkt Cap$86.42M
Float38.26M
O/S45.25M
Inst Own22.2%
SI12.1%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$8K
Net Income-$32.15M
Total Assets$19.03M
Free Cash Flow-$26.37M
Debt & Equity
Debt 13%
Equity 87%
Total Debt$1.69M
Total Equity$11.54M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in GNLX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$19.03M
Liabilities$7.48M
Accounts Receivable$0
Accounts Payable$4.36M
Inventory$0
PP&E (Net)$3.75M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $8K | $8K | $170K | $11.07M | $0 | $0 | $0 |
| YoY Growth | 0.0% | -95.3% | -98.5% | - | - | - | - |
| Cost of Revenue | $574K | $903K | $1.02M | $968K | $895K | $658K | $0 |
| Gross Profit | -$566K | -$895K | -$848K | $10.1M | -$895K | -$658K | $0 |
| Gross Margin | -7075.0% | -11187.5% | -498.8% | 91.3% | - | - | - |
| Research and Development | $19.85M | $19M | $12.77M | $9.08M | $6.32M | $6.23M | $7.53M |
| Selling, General, and Administrative | $13.37M | $12.71M | $11.57M | $5M | $8.29M | $6.2M | $3.34M |
| Other | -$574K | -$903K | -$1.02M | -$968K | -$895K | -$658K | $0 |
| Total Operating Expenses | $32.65M | $30.8M | $23.32M | $13.11M | $13.72M | $11.76M | $10.87M |
| Operating Income (EBIT) | -$33.21M | -$31.7M | -$24.16M | -$3.01M | -$14.61M | -$12.42M | -$10.87M |
| Operating Margin | -415175.0% | -396200.0% | -14214.7% | -27.2% | - | - | - |
| Interest Expense | $0 | $0 | $3.97M | $1.41M | $1.81M | $1.22M | $761K |
| Interest Income | $1.07M | $1.46M | $244K | $0 | $0 | $0 | $0 |
| Other Income (Expense) | $1.07M | $1.83M | -$4.13M | -$1.09M | -$1.76M | -$1.22M | -$761K |
| Income Before Tax (EBT) | -$32.15M | -$29.87M | -$28.3M | -$4.11M | -$16.38M | -$13.64M | -$11.63M |
| Income Tax Expense | $0 | $0 | $0 | $1.1M | $0 | $0 | $0 |
| Net Income | -$32.15M | -$29.87M | -$28.3M | -$5.21M | -$17.8M | -$14.86M | -$11.63M |
| Net Income Margin | -401812.5% | -373362.5% | -16645.3% | -47.0% | - | - | - |
| Supplementary Data | |||||||
| EPS | -0.86 | -0.95 | -1.16 | -0.21 | -0.69 | -0.58 | -0.49 |
| Diluted EPS | -0.86 | -0.95 | -1.16 | -0.21 | -0.69 | -0.58 | -0.49 |
| Weighted Average OS | 37.18M | 31.45M | 24.43M | 24.55M | 23.62M | 23.62M | 23.62M |
| EBITDA | -$31.57M | -$28.97M | -$26.46M | -$1.73M | -$13.67M | -$11.76M | -$10.39M |
| EBITDA Margin | -394637.5% | -362075.0% | -15562.9% | -15.6% | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $5.33M | $8.56M | $9.42M | $397K | $4.5M | $11.35M | $425K |
| Short-Term Investments | $9.26M | $22.33M | $13.77M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $14.6M | $30.89M | $23.19M | $397K | $4.5M | $11.35M | $425K |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $535K | $653K | $1.01M | $1.5M | $0 | $0 | $126K |
| Total Current Assets | $15.13M | $31.55M | $24.2M | $1.89M | $5.82M | $11.48M | $551K |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $3.75M | $3.08M | $3.6M | $1.98M | $2.21M | $2.45M | $2.65M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $144K | $92K | $92K | $1.66M | $92K | $80K | $80K |
| Total Long-Term Assets | $3.9M | $3.17M | $3.69M | $3.64M | $2.3M | $2.53M | $2.73M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $19.03M | $34.72M | $27.89M | $5.53M | $8.13M | $14.01M | $3.28M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $4.36M | $5.57M | $3.78M | $6.78M | $4.46M | $927K | $0 |
| Short-Term Debt | $0 | $329K | $0 | $16.4M | $6.16M | $3.6M | $4.61M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $170K | $4.5M | $0 | $0 |
| Other Current Liabilities | $0 | $0 | $0 | $5.16M | $4.11M | $6.84M | $10.12M |
| Total Current Liabilities | $6.22M | $6.9M | $6.55M | $31.63M | $22.48M | $14.49M | $14.73M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $8.52M | $18.02M | $21.69M | $13.04M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $1.26M | $1.54M | $1.87M | $9.69M | $18.75M | $22.17M | $13.37M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $7.48M | $8.44M | $8.42M | $41.31M | $41.24M | $36.66M | $28.09M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $22K | $22K | $22K | $22K |
| Common Stock | $38K | $35K | $27K | $9K | $9K | $27K | $24K |
| Retained Earnings | -$283.54M | -$251.39M | -$221.52M | -$189.78M | -$184.58M | -$168.23M | -$154.59M |
| Comprehensive Income & Other | $9K | $64K | $14K | $2K | $2K | $2K | $2K |
| Other Stockholders' Equity | $295.04M | $277.63M | $240.97M | $153.99M | $151.46M | $145.55M | $129.75M |
| Total Equity | $11.54M | $26.27M | $19.47M | -$35.78M | -$33.11M | -$22.66M | -$24.81M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $19.03M | $34.72M | $27.89M | $5.53M | $8.13M | $14.01M | $3.28M |
| Supplementary Data | |||||||
| Total Debt | $1.69M | $1.87M | $2.52M | $26.35M | $25.31M | $26.06M | $17.97M |
| Net Debt | -$3.65M | -$6.7M | -$6.9M | $25.96M | $20.82M | $14.71M | $17.55M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$32.15M | -$29.87M | -$28.3M | -$5.21M | -$16.38M | -$13.64M | -$11.63M |
| Depreciation & Amortization | $574K | $903K | $1.02M | $968K | $895K | $658K | $477K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $348K | $0 | $0 |
| Stock-Based Compensation | $5.87M | $6.07M | $5.2M | $2.42M | $4.27M | $5.33M | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$1.21M | $2.16M | -$2.36M | $0 | $754K | -$126K | $0 |
| Other Working Capital | $167K | -$1.41M | -$923K | -$1.69M | $3.33M | $507K | $84K |
| Total Working Capital Change | -$1.05M | $751K | -$3.28M | -$1.69M | $4.08M | $381K | $84K |
| Other Non-Cash Items | $1.48M | $917K | $5.08M | -$56K | $196K | $74K | $3.85M |
| Net Cash from Operating | -$25.27M | -$21.23M | -$20.27M | -$3.57M | -$6.58M | -$7.21M | -$7.22M |
| Investing Activities | |||||||
| Capital Expenditures | -$1.1M | -$381K | -$1.02M | -$49K | $0 | -$20K | -$1.77M |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$18.26M | -$29M | -$13.7M | $0 | $0 | $0 | $0 |
| Sales of Investments | $31.5M | $21.25M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $12.14M | -$8.13M | -$14.72M | -$49K | $0 | -$20K | -$1.77M |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | -$970K | $558K | -$9.16M | -$1.5M |
| Common Stock Issuance | $9.89M | $27.82M | $39.65M | $120K | $143K | $8.99M | $6.38M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $688K | $4.16M | -$1.57M | $145K | $0 | $0 |
| Net Cash from Financing | $9.89M | $28.51M | $44.02M | -$478K | -$270K | $18.15M | $7.89M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$3.23M | -$853K | $9.02M | -$4.1M | -$6.86M | $10.93M | -$1.11M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$25.27M | -$21.23M | -$20.27M | -$3.57M | -$6.58M | -$7.21M | -$7.22M |
| Capital Expenditure | -$1.1M | -$381K | -$1.02M | -$49K | $0 | -$20K | -$1.77M |
| Free Cash Flow | -$26.37M | -$21.61M | -$21.3M | -$3.62M | -$6.58M | -$7.22M | -$8.99M |
| Cash at Beginning | $8.56M | $9.42M | $397K | $4.5M | $11.35M | $425K | $1.53M |
| Cash at End | $5.33M | $8.56M | $9.42M | $397K | $4.5M | $11.35M | $425K |